Mountain Range
Background-01.png

Digital Therapeutics

Arrow_Down-01.png
 

Digital therapeutics (DTx) are digital interventions with clearance from a regulatory body to prevent, manage and treat a disorder or disease aiming for a clinical outcome.

Nephrology-04.png

Our therapeutic focus:

Nephrology

  • Chronic kidney disease (CKD) affects several hundred million patients globally and more than 3 million patients globally undergo regular dialysis treatments due to end-stage-renal-disease (ESRD)
     

  • We are developing the go-to digital therapeutics toolkit for slowing down CKD progression, delaying the start of dialysis and avoiding serious medical complications in dialysis care

 
 

Phase 1

Exploration

Phase 1

Exploration

Phase 1

Exploration

Phase 2

Design & POC

Our DTx product pipeline

Nephrology-04.png

Nephrology

Hypervolemia

CX Miku 501

Hypertension

CX Miku 502

Hyperphosphatemia

CX Miku 503

Hyperkalemia

CX Miku 504

CKD Prevention

CX Miku 340

ESRD Delay

CX Miku 450

Phase 1

Exploration

Phase 2

Design & POC

Phase 3

Pivotal Trial

Phase 4

Regulatory

Phase 5

Launch

Cardiology-04.png

Cardiology

Confidential

Orthopedics

orthopedics-04.png

Confidential

Oncology-04.png

Oncology

Confidential

 
English Sample.gif

The patient companion app for chronic kidney disease is now widely available!

 

We are currently developing the first suite of digital therapeutics for dialysis patients to expand MIKU’s product offering.

Download-On-The-App-Store-PNG-Clipart.pn
google-play-badge-logo-png-transparent.p

Our first product: MIKU
The go-to app for dialysis patients

Further therapeutic areas under development

Cardiology-04.png

Cardiology

orthopedics-04.png

Orthopedics

Oncology-04.png

Oncology